Navigation Links
MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
Date:12/26/2008

First and Only Treatment Approved by the Fda For Hypotrichosis of Eyelashes

The U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE(TM) is the first and only FDA-approved, science-based treatment to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.

Available only through a doctor, LATISSE(TM) is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE(TM) users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE(TM) is required. If use of LATISSE(TM) is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).

LATISSE(TM) will be available in the United States by prescription only and is subject to all U.S. guidelines applicable to dispensing a prescription medical product. Based on today's FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009. Doctors and consumers are encouraged to visit www.latisse.com for further product and prescribing information.

IMPORTANT LATISSE(TM) SAFETY INFORMATION

LATISSE(TM) solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN(R) or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE(TM) under the close supervision of your doctor.

LATISSE(TM) use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE(TM) use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.

It is possible for hair growth to occur in other areas of your skin that LATISSE(TM) frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if you stop using LATISSE(TM).

The most common side effects after using LATISSE(TM) solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE(TM) solution may cause other less common side effects which typically occur on the skin close to where LATISSE(TM) is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.

If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your doctor's advice concerning the continued use of LATISSE(TM) solution.

Full prescribing information is available at www.latisse.com and www.allergan.com.

    SATELLITE FEEDS:
    Friday, December 26th, 2008        Monday, December 29th, 2008
    1:15 PM - 1:30 PM ET               1:00 PM - 1:15 PM ET
    AMC 3                              AMC 3
    C-Band                             C-Band
    Transponder 19                     Transponder 3
    Downlink Freq. 4080 Horizontal     Downlink Freq. 3760 Horizontal

NEWS: U.S Food and Drug Administration (FDA) Approves LATISSE(TM) -- First and Only FDA Approved Treatment to Enhance Eyelash Prominence, including Length, Thickness and Darkness.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/36437/press.html


    SOUNDBITES:
    * Frederick Beddingfield, III, MD, PhD, Chief Medical Officer for
      Allergan Medical and Vice President and Therapeutic Area Head for
      Dermatology Clinical Research and Development at Allergan
    * Doris Day, MD, LATISSE(TM) Clinical Investigator
    * Cindy Ross, LATISSE(TM) Clinical Trial Patient
    * Diane Diamondstein, LATISSE(TM) Clinical Trial Patient

    B-ROLL INCLUDES:
    * Close-up of eyes and eyelashes
    * Photo of patient applying LATISSE(TM)
    * Patient before and after photos

VIDEO PROVIDED BY: Allergan, Inc.

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Allergan, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season
2. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
3. MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device
4. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
5. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
6. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
7. New Online Video Features Brazilian Researcher Elbio Rech
8. Video: 8-Minute Film Documentary Explores Why Humans Age
9. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
10. Video: Insulet Unveils Video Contest for OmniPod Users
11. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ ... board of directors. This addition continues to strengthen and diversify VIC’s board. , ... and Chairman. “He is a highly accomplished business executive with a broad range of ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017   KCNQ2 ... personalized genetic evaluations company, today announced that they ... investigating a genetic mutation implicated in KCNQ2 epileptic ... partnership for a second case involving an additional ... KCNQ2 Cure Alliance and Pairnomix entered into a ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to make clinical trial sites and study participants truly unified. TrialKit, a native ... (FDA 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, ...
(Date:7/18/2017)... , ... July 18, 2017 , ... Sourcing custom glass ... your needs and has the capabilities to properly execute your job can take many ... is a sourcing portal designed to showcase the company’s capabilities and core ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):